---

14 Oct 2008 : Column 1158W—continued

Berkeley Hospital

Mr. Drew: To ask the Secretary of State for Health what progress has been made on the re-location of Berkeley hospital to the Cam/Dursley area. [225424]

Mr. Bradshaw: This information is not held centrally. It is for the local national health service to determine how best to provide services for their local communities. My hon. Friend may wish to contact Jan Stubbings, chief executive of Gloucestershire primary care trust directly, in order for her to deal with the issues raised.

14 Oct 2008 : Column 1159W

Blood: Finance

Mr. Laxton: To ask the Secretary of State for Health what estimate his Department has made of the effect on NHS costs of use of pathogen inactivation for blood products. [225935]

Dawn Primarolo: Pathogen inactivation is currently carried out for a limited number of blood products, not all of which are centrally procured, and it is not therefore possible to estimate the costs to the NHS. However, the Advisory Committee on the Safety of Blood, Tissues and Organs will be undertaking a comprehensive review of pathogen inactivation for blood products in 2009. This will include a full assessment of the costs of interventions and cost-benefit analysis.

Cancer: Health Services

Mr. Lansley: To ask the Secretary of State for Health with reference to his Department's Cancer Reform Strategy published in December 2007, if he will place in the Library the data from which the graphs on pages (a) 88, (b) 120 and (c) 121 were drawn. [224303]

Ann Keen: The data represented in the graph on page 88 of the Cancer Reform Strategy (Proportion of patients in England and Wales in the various age bands who received any active anti-cancer treatment) are set out in the following table. This table has been taken from page 34 (figure 8.4.10) of the National Lung Cancer Audit Report 2006. The table shows any active anti-cancer treatments received by lung cancer patients first seen in 2006 by age groups for all lung cancers, excluding small cell carcinoma.

Any anti-cancer treatment by age group—all lung cancers excluding small cell carcinoma
Age group	Count	Percentage
-54	718	62
55-59	799	61
60-64	1,101	59
65-69	1,329	55
70-74	1,321	50
75-79	1,287	41
80-84	643	28
85+	181	13
Total	7,379	46

14 Oct 2008 : Column 1160W

The report is available on the NHS Information Centre's website at:

www.ic.nhs.uk/our-services/improving-patient-care/national-clinical-audit-support-programme-ncasp/audit-reports/lung-cancer.

A table setting out the data represented in the graph on page 120 of the Cancer Reform Strategy (Spending on cancer in 2006-07 as percentage total of primary care trust (PCT) programme spend) has been placed in the Library. The graph is based on programme budgeting data, collected as part of the annual accounts process. PCT level programme budgeting data are published annually in the form of an interactive Excel spreadsheet on the Department of Health's website at:

www.dh.gov.uk/en/Managingyourorganisation/Financeandplanning/Programmebudgeting/DH_075743.

A table setting out the data represented in the bar chart on page 121 of the Cancer Reform Strategy (Estimated cost per head of NICE-approved cancer drugs used in hospitals in January to June 2005, by cancer network) has been placed in the Library. This analysis was carried out by the Department and the calculations are based on information on volumes of NICE-approved cancer drugs dispensed (from IMS Health (an international consulting and data services company) and cancer network data) and the lowest list prices of those drugs.

Care Homes

Mr. Lansley: To ask the Secretary of State for Health what data his Department holds on the latest standard rate for local authority-provided residential care in each local authority area. [226303]

Phil Hope: None. Information on the fees negotiated by local authorities with providers of care is not collected centrally.

CJD: Death

Mr. Hancock: To ask the Secretary of State for Health how many people have died from (a) sporadic Creutzfeldt-Jakob disease (CJD) and (b) variant CJD in the last 20 years. [226279]

Dawn Primarolo: Information on all Creutzfeldt-Jakob Disease (CJD) deaths in the United Kingdom collected since the establishment of the National Creutzfeldt-Jakob Disease Surveillance Unit in 1990 is in the following table:

14 Oct 2008 : Column 1161W

14 Oct 2008 : Column 1162W

CJD in the United Kingdom (by calendar year)—data to 6 October 2008
Referrals of suspect CJD		Deaths of definite and probable CJD
Year	Referrals	Year	Sporadic	Iatrogenic	Familial	Gertmann Straussler Scheinker Disease	Variant Creutzfeldt Jakob Disease	Total d eaths
1990	53	1990	28	5	0	0	0	33
1991	75	1991	32	1	3	0	0	36
1992	96	1992	45	2	5	1	0	53
1993	78	1993	37	4	3	2	0	46
1994	118	1994	53	1	4	3	0	61
1995	87	1995	35	4	2	3	3	47
1996	133	1996	40	4	2	4	10	60
1997	162	1997	60	6	4	1	10	81
1998	154	1998	63	3	3	2	18	89
1999	170	1999	62	6	2	0	15	85
2000	178	2000	50	1	2	1	28	82
2001	179	2001	58	4	4	2	20	88
2002	163	2002	72	0	4	1	17	94
2003	162	2003	79	5	4	2	18	108
2004	114	2004	50	2	4	2	9	67
2005	124	2005	66	4	8	5	5	88
2006	110	2006	68	1	6	3	5	83
2007	115	2007	62	2	7	1	5	77
2008	99	2008	59	4	1	3	1	68
Total referrals	2,370	Total deaths	1,019	59	68	36	164	1,346
Source: National Creutzfeldt-Jakob Disease Surveillance Unit http://www.cjd.ed.ac.uk/

---